Thyroid-related adverse events induced by immune checkpoint inhibitors

Immune checkpoint inhibitors, namely anti-CTLA-4, anti-PD-1 and anti-PD-L1 monoclonal antibodies, have emerged in the last decade as a novel form of cancer treatment, promoting increased survival in patients. As they tamper with the immune response in order to destroy malignant cells, a new type of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chera, Alexandra, Stancu, Andreea Lucia, Bucur, Octavian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530140/
https://www.ncbi.nlm.nih.gov/pubmed/36204105
http://dx.doi.org/10.3389/fendo.2022.1010279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530140/
https://www.ncbi.nlm.nih.gov/pubmed/36204105
http://dx.doi.org/10.3389/fendo.2022.1010279

Ejemplares similares